Business
Parsortix breakthrough in prostate cancer
Parsortix breakthrough in prostate cancer.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1286I Angle PLC 15 June 2017 \n\n\n\n\n\nFor immediate release\n\n\n 15 June 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nPARSORTIX BREAKTHROUGH DELIVERS RARE BLOOD CELL DISCOVERY IN PROSTATE CANCER \n \nBarts Cancer Institute study finds rare type of cell in cancer patient blood linked to survival\n \nUse of Parsortix identifies patients that are 10 times more likely to die of their disease early\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that researchers from Queen Mary University of London's Barts Cancer Institute (BCI), using ANGLE's Parsortix system, have found a rare cell, known as a megakaryocyte, in the blood of prostate cancer patients and discovered that the number of these cells in the blood correlates closely with increased patient survival. This is the first time the presence of these cells in the blood has been shown to be connected to cancer prognosis. \n \nThe consequence of this finding is that, from a simple blood test, the Parsortix system has been shown to be capable of harvesting for analysis not only mesenchymal CTCs, which are linked to a poor outcome, but also megakaryocytes, which are linked to a favourable patient outcome. BCI researchers have shown in a 40 patient study that combining these two factors enables the identification of patients, who are 10 times more likely to die of their disease in the short term. This knowledge may enable targeted treatment, potentially improving patient outcomes.\n \nInvestigation of megakaryocytes in patient blood opens up a whole new area for cancer research and, at present, ANGLE's patented Parsortix system is the only system that has been demonstrated to be capable of harvesting megakaryocytes. \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"This is a key breakthrough for ANGLE's Parsortix system showing further unique capabilities to harvest both rare megakaryocyte cells and mesenchymal CTCs in patient blood that play an essential role in the process of metastasis, which is responsible for over 90% of cancer deaths worldwide. The findings of this study are of great medical potential, demonstrating an ability to identify patients most at risk of aggressive p...